🎉 M&A multiples are live!
Check it out!

I-MAB Valuation Multiples

Discover revenue and EBITDA valuation multiples for I-MAB and similar public comparables like Pharming, Galapagos, and Vivoryon Therapeutics.

I-MAB Overview

About I-MAB

I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People’s Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).


Founded

2016

HQ

United States of America
Employees

32

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

-$91.6M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

I-MAB Financials

I-MAB has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, I-MAB achieved revenue of n/a and an EBITDA of -$49.2M.

I-MAB expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See I-MAB valuation multiples based on analyst estimates

I-MAB P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $3.9M n/a XXX XXX XXX
Gross Profit -$36.1M $3.9M XXX XXX XXX
Gross Margin -925% Infinity% XXX XXX XXX
EBITDA -$199M -$49.2M XXX XXX XXX
EBITDA Margin -5109% -Infinity% XXX XXX XXX
Net Profit -$363M -$207M XXX XXX XXX
Net Margin -9319% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

I-MAB Stock Performance

As of April 15, 2025, I-MAB's stock price is $1.

I-MAB has current market cap of $77.9M, and EV of -$91.6M.

See I-MAB trading valuation data

I-MAB Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$91.6M $77.9M XXX XXX XXX XXX $-0.16

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

I-MAB Valuation Multiples

As of April 15, 2025, I-MAB has market cap of $77.9M and EV of -$91.6M.

I-MAB's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate I-MAB's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for I-MAB and 10K+ public comps

I-MAB Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$91.6M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA 1.9x XXX XXX XXX
P/E -3.5x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 1.7x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get I-MAB Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

I-MAB Valuation Multiples

I-MAB's NTM/LTM revenue growth is n/a

I-MAB's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.6M for the same period.

Over next 12 months, I-MAB's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate I-MAB's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for I-MAB and other 10K+ public comps

I-MAB Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -100% XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth -75% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $1.6M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

I-MAB Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Vaccines & Immunotherapies comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

I-MAB M&A and Investment Activity

I-MAB acquired  XXX companies to date.

Last acquisition by I-MAB was  XXXXXXXX, XXXXX XXXXX XXXXXX . I-MAB acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by I-MAB

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About I-MAB

When was I-MAB founded? I-MAB was founded in 2016.
Where is I-MAB headquartered? I-MAB is headquartered in United States of America.
How many employees does I-MAB have? As of today, I-MAB has 32 employees.
Who is the CEO of I-MAB? I-MAB's CEO is Dr. Xi-Yong Sean Fu.
Is I-MAB publicy listed? Yes, I-MAB is a public company listed on NAS.
What is the stock symbol of I-MAB? I-MAB trades under IMAB ticker.
When did I-MAB go public? I-MAB went public in 2020.
Who are competitors of I-MAB? Similar companies to I-MAB include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of I-MAB? I-MAB's current market cap is $77.9M
Is I-MAB profitable? Yes, I-MAB is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.